Search the Newsreel

Wells Fargo Adjusts PT on Mettler-Toledo International to $1,450 From $1,225, Keeps Equalweight Rating

Wells Fargo has increased its price target for Mettler-Toledo International (MTD) to $1,450 from $1,225, while maintaining an Equalweight rating on the stock. This adjustment comes amidst recent analyst actions, with other firms like Morgan Stanley, Stifel, and Goldman Sachs also updating their price …

AstraZeneca tops pharma growth rankings while Bristol Myers trails amid merger talks (XLV:NYSEARCA)

AstraZeneca leads pharmaceutical growth rankings with an 'A' Growth Grade, while Bristol Myers Squibb lags with a 'D' grade. This comes amidst reports that the two companies are exploring a merger, which would create one of the world's largest pharmaceutical firms. A merger would …

AstraZeneca falls to third-largest UK company amid US merger talks

AstraZeneca's market value dropped by over £17bn after reports emerged of its discussions to acquire US rival Bristol Myers Squibb for nearly $400bn, causing it to lose its position as the second-largest UK company to Shell. Analysts and shareholders have expressed skepticism about the …

Analysts baffled by AstraZeneca's interest in Bristol Myers Squibb

Analysts are perplexed by AstraZeneca's reported interest in acquiring Bristol-Myers Squibb, especially given AstraZeneca's strong growth and innovation. Both Jefferies and UBS, while maintaining 'buy' ratings on AstraZeneca, raised concerns about the strategic fit, potential pipeline overlap, looming patent expiries for Bristol-Myers Squibb's key …

Capitol Federal Financial (NASDAQ:CFFN) Reaches New 1-Year High - Here's What Happened

The $400 Billion Reason Bristol-Myers Squibb (BMY) Stock Is Up Today

Dimensional Fund Advisors LP Purchases 263,238 Shares of Capitol Federal Financial $CFFN

Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Up - Still a Buy?

Bristol Myers Squibb (BMY) In Early Merger Talks With AstraZeneca

Noida Toll Bridge Q1FY27 net profit rises 28.7% as court stays fee demand

AstraZeneca slides after reports of Bristol Myers merger talks leave analysts 'perplexed'

AstraZeneca's stock fell sharply after reports emerged of potential merger talks with Bristol Myers Squibb, a deal that could create a $400 billion pharmaceutical giant. Analysts expressed bewilderment over the strategic rationale, given AstraZeneca's strong growth and pipeline, while Bristol Myers faces upcoming patent …

Capitol Federal Financial (CFFN) Following Q3 Results And Buybacks, Is The Stock Already Priced In?

Capitol Federal Financial (CFFN) has garnered renewed interest following its Q3 2026 results, cash dividend affirmation, and share repurchase program. While the stock's Price-to-Earnings ratio of 13.3x suggests it's slightly overvalued compared to its US Banks peers and its estimated fair multiple of 11.9x, …

AstraZeneca, Bristol Myers Squibb Reportedly in Talks for $400 Billion Merger

AstraZeneca and Bristol Myers Squibb are reportedly in discussions for a merger that could create a pharmaceutical giant valued at approximately $400 billion. The talks have been ongoing for several months and, if successful, would make AstraZeneca the world’s fourth-largest drugmaker by market capitalization. …

AstraZeneca holds talks with Bristol Myers Squibb on $400 billion megadeal, FT reports

AstraZeneca has reportedly held talks with Bristol Myers Squibb regarding a potential merger that could create a pharmaceutical giant valued at nearly $400 billion. The Financial Times reported on Sunday that discussions have occurred in recent months, though a deal could still be delayed …

AstraZeneca, Bristol Myers held merger talks, Financial Times reports (AZN:NYSE)

AstraZeneca (AZN) and Bristol Myers Squibb (BMY) reportedly held preliminary discussions regarding a potential merger. This combination, if it materializes, would result in one of the world's largest pharmaceutical companies. The news was reported by the Financial Times.

AstraZeneca, Bristol Myers Squibb Held Talks for Tie-Up, FT Says

AstraZeneca Plc and Bristol Myers Squibb Co. reportedly held discussions about a potential merger to combine the two pharmaceutical companies. The Financial Times, citing familiar sources, stated that these talks occurred in recent months, though the specifics of the deal structure were not detailed …

Bristol-Myers Squibb Company supera las previsiones de los analistas: descubre cuáles son las previsiones de consenso para este año

Renaissance Technologies LLC Acquires Shares of 8,350 Mettler-Toledo International, Inc. $MTD

Renaissance Technologies LLC has acquired 8,350 shares of Mettler-Toledo International, Inc. (NYSE:MTD) valued at approximately $10,531,000 during the first quarter. Other institutional investors also adjusted their positions in MTD. The company recently reported strong quarterly earnings, exceeding expectations, and raised its full-year outlook, while …

Mettler-Toledo (MTD) Is Up 6.7% After Raising 2026 Outlook And Announcing $875 Million Buyback

Bristol-Myers Squibb Company Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Quantinno Capital Management LP Has $27.38 Million Stake in Mettler-Toledo International, Inc. $MTD

Quantinno Capital Management LP significantly increased its stake in Mettler-Toledo International, Inc. by 12.3% in the first quarter of 2026, bringing its total holding to 21,708 shares valued at $27.38 million. This comes as Mettler-Toledo reported strong quarterly earnings, beating expectations with adjusted EPS …

Mettler-Toledo International, Inc. $MTD Shares Sold by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company has reduced its stake in Mettler-Toledo International, Inc. (MTD) by 4.2%, selling 937 shares but still retaining 21,571 shares valued at approximately $27.2 million. This comes as Mettler-Toledo exceeded quarterly earnings expectations with an adjusted EPS of $11.46 and …

Mettler Toledo (MTD) Stock Jumps On EPS Beat As Valuation Debate Deepens

California State Teachers Retirement System Reduces Position in Mettler-Toledo International, Inc. $MTD

Final home sections open at Pecan Ridge | Tri Pointe Homes

Pecan Ridge, a master-planned community in Fulshear built by Tri Pointe Homes and Toll Brothers, is opening its final home sections. The community offers homes starting in the mid-$300s, with various floor plans and lot sizes, and is zoned to Lamar CISD. Residents can …

XS259833213 Bond Profile — Key Metrics

This article provides key metrics for the Autoliv, Inc. 4.25% 15-MAR-2028 bond, identified by XS259833213, traded on the Munich Stock Exchange. It details the issuer, issue and maturity dates, outstanding amount, face value, minimum denomination, and coupon rate. Autoliv, Inc. is described as a …

BMY Q2 Deep Dive: Growth Portfolio and Pipeline Progress Drive Upgraded Outlook

BMY Q2 Deep Dive: Growth Portfolio and Pipeline Progress Drive Upgraded Outlook Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) reported Q2 CY2026 results exceeding the market's revenue expectations , with sales up 5.7% year on year to $12.97 billion. The company's full-year revenue guidance of …

Is Capitol Federal’s Strong Q3, Dividend and Buyback Spree Altering The Investment Case For CFFN?

Capitol Federal Financial (CFFN) recently reported strong Q3 2026 results, including increased net interest income and net income, low charge-offs, and a reaffirmed dividend. The company also completed a significant share repurchase program, highlighting management's commitment to capital return. While CFFN's investment narrative focuses …

Mettler-Toledo International Q2 Earnings Call Highlights

Key Points Interested in Mettler-Toledo International, Inc.? Here are five stocks we like better. Q2 results exceeded expectations: Sales rose 7% in U.S. dollars to $1 billion, while adjusted EPS increased 14% to $11.46. Growth was supported by China and emerging markets, Laboratory and …

BRISTOL-MYERS SQUIBB COMPANY

Bristol-Myers Squibb Company : Consenso de Precios Objetivo y Recomendaciones de los Analistas | BMY | US1101221083

Mettler-Toledo International (NYSE:MTD) Price Target Raised to $1,580.00 at Jefferies Financial Group

Jefferies Financial Group has increased its price target for Mettler-Toledo International (NYSE:MTD) to $1,580.00 from $1,400.00, maintaining a "Buy" rating. This adjustment suggests an 11.64% potential upside from the stock's previous closing price. The company recently reported strong quarterly earnings of $11.46 per share, …

JPMorgan Adjusts Price Target on Mettler-Toledo International to $1,400 From $1,200

JPMorgan has increased its price target for Mettler-Toledo International (NYSE:MTD) to $1,400, up from the previous target of $1,200. The firm maintained its "Overweight" rating on the company's stock. This adjustment reflects a more optimistic outlook by JPMorgan on Mettler-Toledo International's future performance.

Mettler-Toledo Earnings: Consensus Beat Drives Second Consecutive Guidance Raise

Mettler-Toledo International Inc (MTD) (Q2 2026) Earnings Call Highlights: Strong Organic ...

This article first appeared on GuruFocus. Release Date: July 31, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Mettler-Toledo International Inc (NYSE:MTD) reported strong Q2 2026 results with better-than-expected organic sales growth of …

Goldman Sachs Raises Price Target on Mettler-Toledo International to $1,440 From $1,340, Maintains Neutral Rating

Goldman Sachs has increased its price target for Mettler-Toledo International (MTD) to $1,440 from $1,340, while reaffirming a Neutral rating on the stock. This adjustment reflects an updated outlook by the firm. The article also lists several other analyst target adjustments for Mettler-Toledo International.